DUBLIN – Alzecure Pharma AB is set to become the latest biotech firm to join the ranks of listed companies in Sweden. The Huddinge-based company last week priced an IPO on the First North Premier exchange at SEK14 (US$1.54) per share. The offer, which comprises about 14.3 million shares, will raise SEK200 million and value the firm at about SEK500 million. It has already received advance commitments covering 77 percent of the base offering. Should demand for shares exceed supply, the company has also put in place an extension option, which would raise another SEK50 million.